LRRK2 · Western blot design guide

LRRK2 Western Blot Planning Guide

Plan a LRRK2 Western blot around the catalog-observed 286.1 kDa band, image-backed PB9281 evidence, HPA controls, and verified protocol records.

Evidence assembled July 2026 · For research use; verify linked source records and product datasheet before use
Western blot protocol sheet for LRRK2 (LRRK2): expected band 286.1 kDa, antibody PB9281, and guide-derived SDS-PAGE protocol steps
LRRK2 Western blot protocol sheet — expected band 286.1 kDa, antibody PB9281, controls and PMC citations. Open the full LRRK2 WB guide →

LRRK2 Western Blot Experimental Design Guide

Expected bands, documented protocol parameters, controls and antibodies — the at-a-glance facts below, then the full design guide.

Must know before running
Expected band 286.1 kDa
Observed band Not reported — verify product WB image
Gel 4-12% gradient
Positive control ⓘ Kidney
Negative control ⓘ Bone marrow
Important caveats
Reasons your observed band may differ from the expected size.
ⓘ Calculated mass 286.1 kDa
ⓘ Localization Cytoplasmic vesicle / Perikaryon
ⓘ Processing / PTM Record-dependent
ⓘ Reactivity Human / Mouse / Rat
Section 1

Real Curated LRRK2 Western Blot Protocols

Start with the molecular-weight rule, then compare verified publication-derived conditions.

Recommended Western blot protocol parameters
Sample / lysateKidney
Gel %4-12% gradient
Load20-30 µg total protein per lane
TransferWet/tank, extended transfer
Membrane0.45 µm PVDF
Blocking5% non-fat milk or 5% BSA in TBST
PrimaryPB9281 at datasheet starting dilution
Primary incubationOvernight at 4 °C with gentle agitation
SecondarySpecies-matched HRP conjugate at validated dilution
Wash3 × 5 min in TBST
DetectionChemiluminescent substrate
ExposureBracket exposures to avoid saturation
Section 2

What Is the Expected LRRK2 Western Blot Band Size?

Use the product-observed 286.1 kDa band as the primary planning value and retain the UniProt calculated mass as context.

What am I looking at on my blot?
286.1 kDaMatches the authoritative product WB observation.
286.1 kDa calculatedUse as UniProt context, not as a replacement observed band.
Unexpected additional signalDo not assign identity without orthogonal positive/negative controls.
💡Expected LRRK2 appearancePlan around 286.1 kDa and keep the calculated mass as supporting context.
How each factor affects band size
Catalog-observed band286.1 kDa; use this as the primary experimental expectation.
Calculated mass286.1 kDa from UniProt Q5S007; retain as context.
Gel selection4-12% gradient; shared with the recommended protocol and poster.
Specificity checkCompare the lead HPA positive and negative controls with PB9281.
Why is my band missing or off?
SituationLikely causeNext action
286.1 kDaMatches the authoritative product WB observation.Confirm with orthogonal controls and the linked product record.
Additional bandMay reflect processing, modification, or non-specific signal.Run a dilution series and compare positive/negative controls.
Weak signalTarget abundance or transfer may be limiting.Verify transfer, increase positive-control abundance, and bracket exposure.

Sample controls for LRRK2 Western blot

🧪Use Kidney as the first positive-control candidate and Bone marrow as the HPA Not detected negative candidate.
Positive control: Kidney (High)
Negative control: Bone marrow (Not detected)
HPA protein score determines control status; other expression data is supporting context only.

HPA tissue expression evidence for LRRK2

Comprehensive Human Protein Atlas IHC scoring per tissue. Rows are taken directly from the HPA tissue chart — click any row's HPA link to view the source.

Positive expression · recommended positive controls

TissueCell typeLevelEvidenceSource
Kidney Reported tissue cells High Protein (HPA) HPA →
Lung Reported tissue cells Medium Protein (HPA) HPA →
Caudate Reported tissue cells Low Protein (HPA) HPA →
Appendix Reported tissue cells Low Protein (HPA) HPA →

Undetected expression · recommended negative controls

TissueCell typeLevelEvidenceSource
Bone marrow Reported tissue cells Not detected Protein (HPA) HPA →
Cerebral cortex Reported tissue cells Not detected Protein (HPA) HPA →
Section 3

Advanced LRRK2 Western Blot Tips

Deeper troubleshooting and optimisation questions for LRRK2, answered from its protein features.

Which band should guide the blot?
Use 286.1 kDa, the observation attached to the authoritative PB9281 WB record.
How should calculated mass be interpreted?
Treat the UniProt calculated mass as context; it does not replace the catalog-observed 286.1 kDa expectation.
Which positive control should I start with?
Start with Kidney, the lead HPA protein-expression candidate.
Which negative control is defensible?
Use Bone marrow as an orthogonal HPA Not detected candidate.
Which gel should I use?
Use 4-12% gradient consistently across the quick facts, protocol table, and poster.
What transfer method to use for LRRK2 Western blot?
Use the transfer method in the recommended protocol and verify transfer before blocking.
How should PB9281 be started?
Start at the linked datasheet condition and run a three-point primary-antibody dilution test.
Which publication-derived protocols can I compare?
No verified publication protocol was supplied; use only the deterministic recommended protocol.
Boster reagents

LRRK2 Western Blot Reagents

Human/Mouse/Rat-reactive LRRK2 Western blot reagents with authoritative product imagery.

Real WB data Western blot validation image for LRRK2 using PB9281; observed band 286.1 kDa
Anti-LRRK2 Antibody Picoband®
Cat # PB9281

Only image-backed, WB-validated Human/Mouse/Rat recommendations from the prepared catalog evidence are shown.

Source: prepared picoband-wb product evidence; each card retains its own SKU, URL, observed band, and authoritative WB image.

References

  1. UniProt Q5S007
  2. Human Protein Atlas — LRRK2
  3. PB9281 product record
  4. PMC7702304 — Endogenous Rab29 does not impact basal or stimulated LRRK2 pathway activity (The Biochemical journal, 2020)
  5. PMC10907374 — G2019S selective LRRK2 kinase inhibitor abrogates mitochondrial DNA damage (NPJ Parkinson's disease, 2024)
  6. PMC3429506 — Screening for novel LRRK2 inhibitors using a high-throughput TR-FRET cellular assay for LRRK2 Ser935 phosphorylation (PloS one, 2012)